Abstract: A pharmaceutical or nutraceutical composition with a core, an inner coating layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, one or more salts of alginic acid is contained in the inner coating layer, and one or more water-insoluble polymers or copolymers is contained in the outer coating layer. In the composition, the ratio of the amount of the one or more salts of alginic acid in the inner coating layer is at least 2.5:1 by weight to the amount of the one or more water-insoluble polymers or copolymers in the outer coating layer.

Abstract: A pharmaceutical or nutraceutical composition with a core, an inner layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, at least 30% by weight of a salt of alginic acid is contained in the inner layer, and at least 30% by weight of a polymer or copolymer with anionic side groups is contained in the outer coating layer.

Abstract: The present invention relates to the field of pharmaceutical and nutraceutical formulations, and, more specifically, to effervescent formulations of ornithine aspartate as well as processes for their manufacture. Formulations of ornithine aspartate according to the present invention comprise a gas generating component as well as an acid component releasing carbon dioxide upon contact with water. The invention provides a simple process for the manufacture of such formulations that are chemically pure and stable and exhibit high levels of effervescence. The process comprises the following steps: —granulation of an ornithine aspartate-mix comprising ornithine aspartate and a gas generating component, thus yielding granules G, —mixing the components of a final mix comprising granules G and an acid component, thus yielding an effervescent formulation of ornithine aspartate.

Abstract: The invention refers to a pharmaceutical or nutraceutical composition comprising a core a) comprising an active ingredient and a water-insoluble polymer, a coating layer b) above the core a) comprising a salt of an alginic acid, and a coating layer c) above the coating layer b) comprising an anionic (meth)acrylate copolymer polymerized from a (meth)acrylate monomer mixture comprising 5-75% by weight in relation to the total weight of the (meth)acrylate monomer mixture of (meth)acrylate monomers with an anionic group, wherein the amount of the water-insoluble polymer in the core a) is 2 to 20% by weight in relation to the weight of the core a) and the amount of the salt of an alginic acid in the coating layer b) is 5 to 85% by weight in relation to the weight of the core a) and the amount of the anionic (meth)acrylate copolymer in the coating layer c) is 10 to 75% by weight in relation to the weight of the core a) and to the coating layer b).

Abstract: The invention refers to a pharmaceutical or nutraceutical composition, comprising a) a core, comprising a pharmaceutical or a nutraceutical active ingredient, b) an inner coating layer comprising one or more salts of alginic acid and c) an outer coating layer comprising one or more water-insoluble polymers or copolymers and one or more water-soluble polymers, selected from the group of water soluble celluloses, polyvinyl pyrrolidones or polyethylene glycols or any combinations thereof. wherein the ratio by weight of the amount of the one or more salts of alginic acid in the inner coating layer to the amount of the one or more water-insoluble polymers or copolymers in outer coating layer is from 0.6 to less than 2.5:1.

Abstract: The invention refers to a pharmaceutical or nutraceutical composition, comprising a) a core, comprising a pharmaceutical or a nutraceutical active ingredient, b) an inner coating layer comprising one or more salts of alginic acid and c) an outer coating layer comprising one or more water-insoluble polymers or copolymers and one or more water-soluble polymers, selected from the group of water soluble celluloses, polyvinyl pyrrolidones or polyethylene glycols or any combinations thereof. wherein the ratio by weight of the amount of the one or more salts of alginic acid in the inner coating layer to the amount of the one or more water-insoluble polymers or copolymers in outer coating layer is from 0.6 to less than 2.5:1.

Abstract: The invention refers to a coating composition which, calculated on dry weight, is comprising at least 20% by weight polyvinyl alcohol and 0.1 to 20% by weight, calculated on the weight of the polyvinyl alcohol, of a water-insoluble (meth)acrylate copolymer comprising quaternary ammonium groups, wherein the viscosity of an aqueous dispersion comprising that coating composition with 25% (w/w) solid content at 22° C. is 200 mPa·s or less.

Abstract: The invention relates to a process for stabilizing the drug release profile of a polymer film coated pharmaceutical composition, wherein the pharmaceutical composition comprises a core comprising an active pharmaceutical ingredient and a polymer film coating onto the core which was applied by a spray coating process, including a subsequent drying step, by applying microwave-irradiation, infrared-irradiation, UV-irradiation or ultra sonic wave irradiation to the polymer film coated pharmaceutical compositions.

Abstract: Multiparticulate pharmaceutical composition comprising a multitude of two kinds of pellets, A and B, each comprising metoprolol or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient, wherein the pellets A are coated with a coating layer comprising at least 30% by weight of a polymeric compound consisting of one or more (meth)acrylate copolymers polymerized from 20 to 40% by weight of ethyl acrylate, 60 to 80% by weight of methyl methacrylate and 0 or less than 5% by weight of methacrylic acid or acrylic acid, in an amount sufficient to result in an active pharmaceutical ingredient release profile according to USP in pH 6.8 test medium with a release rate of less than 20% after 4 hours, wherein the pellets B are not coated or coated with a coating layer and show an active pharmaceutical ingredient release profile according to USP in pH 6.

Abstract: The invention discloses a process for preparing granulated product from a powder composition comprising the mixed components (a) and (b) and (c) or (d) or both, with (a), a copolymer consisting of free-radical-polymerized C1- to C4-esters of acrylic or methacrylic acid and alkyl(meth)acrylate monomers with tertiary amino groups in the alkyl side groups (b) 5 to 25% by weight, based on (a), of a C12- to C18-monocarboxylic acid or a C12- to C18-alcohol, (c) 0 to 10% by weight based on (a) of a dicarboxylic acid having 3 to 10 carbon atoms, (d) 0 to 20% by weight, based on (a), of an emulsifier having an HLB of at least 14, wherein the mixed components are processed by a dry granulation process to a granulate with a mean particle size of 2 mm or less.

Abstract: The invention discloses a process for preparing aqueous dispersions comprising the components (a) and (b) and optionally (c) or (d) or both, (a) a copolymer consisting of free-radical-polymerized C1- to C4-esters of acrylic or methacrylic acid and alkyl(meth)acrylate monomers with tertiary ammonium groups in the alkyl side groups, (b) 5 to 25% by weight, based on (a), of a C12- to C18-monocarboxylic acid or a C12- to C18-alcohol, (c) 0 to 10% by weight based on (a) of a dicarboxylic acid having 3 to 10 carbon atoms, (d) 0 to 20% by weight, based on (a), of an emulsifier having an HLB of at least 14 by dispersing the components in water where the water has a temperature of more than 40 and up to 85° C., where the solid content of the dispersion is from 5 to 40% by weight and where a clear colloidal dispersion is obtained in less than 30 min.

Abstract: A pharmaceutical or nutraceutical composition with a core, an inner layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, at least 30% by weight of a salt of alginic acid is contained in the inner layer, and at least 30% by weight of a polymer or copolymer with anionic side groups is contained in the outer coating layer.

Abstract: A pharmaceutical or nutraceutical composition with a core, an inner coating layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, one or more salts of alginic acid is contained in the inner coating layer, and one or more water-insoluble polymers or copolymers is contained in the outer coating layer. In the composition, the ratio of the amount of the one or more salts of alginic acid in the inner coating layer is at least 2.5:1 by weight to the amount of the one or more water-insoluble polymers or copolymers in the outer coating layer.